Part 6/8:
Convenience is often the least discussed factor but holds substantial weight in patient adherence and overall drug effectiveness. A drug with a complicated administration schedule may suffer from lower patient compliance, detracting from its efficacy in practice. The ongoing competition within the PD-1 cancer treatment landscape, particularly between Bristol-Myers Squibb’s Opdivo and Merck’s Keytruda, exemplifies this. Recent changes to Opdivo’s dosing schedule that allow for less frequent administration could influence its ability to reclaim market share.